Safety Study of SPARC1104

NCT01797185 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

375

Enrollment

INDUSTRY

Sponsor class

Conditions

Spasticity

Interventions

DRUG: SPARC1104 modified dose regimen I
DRUG: SPARC1104 modified dose regimen II
DRUG: SPARC1104 modified dose regimen III

Sponsor

Sun Pharma Advanced Research Company Limited